Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer

Published:2016-12-19 Issue:5 Volume:77 Page:479-488
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Alva Ajjai¹,Nordquist Luke²,Daignault Stephanie¹,George Saby³,Ramos Jorge⁴,Albany Costantine⁵,Isharwal Sudhir²,McDonald Matthew²,Campbell Gregory¹,Danchaivijitr Pongwut³,Yentz Sarah¹,Anand Aseem⁶,Yu Evan Y.⁴

Affiliation:

1. Division of Hematology/Oncology; University of Michigan; Ann Arbor Michigan

2. Urology Cancer Center and GU Research Network; Omaha Nebraska

3. Roswell Park Cancer Institute; Buffalo New York

4. Fred Hutchinson Cancer Research Center; Seattle Washington

5. Indiana University Melvin and Bren Simon Cancer Center; Indianapolis Indiana

6. Department of Translational Medicine, Urological Cancer; Lund University; Lund Sweden

Funder

Bayer Pharmaceuticals

Publisher

Wiley

Subject

Urology,Oncology

Reference26 articles.

1. 2015 http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf

2. Mechanisms of androgen-refractory prostate cancer;Debes;N Engl J Med,2004

3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial;de Bono;Lancet,2010

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra;Cancers;2024-07-29

2. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial;Cancers;2023-05-16

3. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters;The Oncologist;2023-01-18

4. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment—Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial;European Journal of Nuclear Medicine and Molecular Imaging;2022-12-21

5. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer;Clinical Cancer Research;2022-11-02